Registration Successful...
null you have successfully logged registered and logged in
Administration

Administering FLUMIST

Administering FLUMIST

See the administration video, followed by important notes, and an illustrated step-by-step guide.

This content is not currently available for your device.

X


FLUMIST can be easy to administer1,2

One spray in each nostril—no sniff required2

  • Patients can breathe normally during administration2
  • No need to re-administer if sneezing, dripping, or swallowing occurs3
    • Patients will receive a sufficient dose even if they sneeze or swallow, or if dripping occurs3
    • FLUMIST is formulated with more attenuated infectious units of each of the 3 component viral strains than needed to develop the immune response2,4
FluMist Quadrivalent Administration Step 1

Check expiration date. Product must be used before the date on sprayer label.

FluMist Quadrivalent Administration Step 2

Remove rubber tip protector. Do not remove dose-divider clip at the other end of the sprayer.

FluMist Quadrivalent Administration Step 3

With the patient in an upright position, place the tip just inside the nostril to ensure FLUMIST is delivered into the nose.

FluMist Quadrivalent Administration Step 4

With a single motion, depress plunger as rapidly as possible until the dose-divider clip prevents you from going further.

FluMist Quadrivalent Administration Step 5

Pinch and remove the dose-divider clip from the plunger.

FluMist Quadrivalent Administration Step 6

Place the tip just inside the other nostril and with a single motion, depress plunger as rapidly as possible to deliver remaining vaccine.

FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) Administration Steps FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) Administration Steps

Dispose of sprayer per standard procedures for medical waste (eg, sharps container or biohazard container).2   


IMPORTANT SAFETY INFORMATION

  • Do not administer FLUMIST to persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine, or to children and adolescents through 17 years of age who are receiving aspirin or aspirin-containing therapy
  • In clinical trials, the risks of hospitalization and wheezing were increased in children younger than 2 years of age who received FLUMIST
  • Children younger than 5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following the administration of FLUMIST. FLUMIST has not been studied in persons with severe asthma or active wheezing
  • If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST should be based on careful consideration of the potential benefits and risks
  • The effectiveness of FLUMIST has not been studied in immunocompromised persons
  • The safety of FLUMIST in individuals with underlying medical conditions that may predispose them to complications following wild-type influenza infection has not been established
  • Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of FLUMIST
  • FLUMIST may not protect all individuals receiving the vaccine
  • The most common solicited adverse reactions (≥10% in vaccine recipients and at least 5% greater than in placebo) reported after FLUMIST were runny nose or nasal congestion (ages 2-49 years), fever >100 °F (children ages 2-6 years), and sore throat (adult ages 18-49 years)

FLUMIST is a vaccine indicated for active immunization of persons 2 through 49 years of age for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUMIST is for intranasal administration only.

Please see full Prescribing Information for FLUMIST, including Patient Information.

You may report side effects related to AstraZeneca products.